

Abteilung "Nephrologie und Rheumatologie"

Journalbeiträge

1. Bramlage P, Heller T, Scheel A, Edinger M, Groenewold F, Koziol M, Müller GA, Strutz F (2007) Brennendes pustulöses Exanthem nach Nierentransplantation. *Der Nephrologe*, 2: 206-210.
2. Bramlage P, Schindler C, Schmidt AC, Bramlage CP, Kirch W (2007) [Recent examples for drug (developments) in primary, secondary and tertiary prevention]. *DEUT MED WOCHENSCHR*, 132(42): 2212-6.
3. Bramlage P, Schindler C, Thoenes M, Bramlage CP, Böcking W, Kirch W (2007) [Prevention of cardiovascular disease by blocking the endocannabinoid system]. *HERZ*, 32(7): 560-7.
4. Bramlage P, Thoenes M, Paar WD, Bramlage CP, Schmieder RE (2007) [Albuminuria: an indicator of cardiovascular risk]. *MED KLIN*, 102(10): 833-43; quiz 844-5.
5. Dihazi H (2007) Clinical proteomics: new trend in urine proteome analysis and biomarker discovery. *European Renal Disease*, II: XX.
6. Dihazi H (2007) Proteomics: Diagnostische Ansätze in der nephrologie. *Med Review*, 12: 12-13.
7. Dihazi H, Müller GA (2007) Urinary proteomics: a tool to discover biomarkers of kidney diseases. *EXPERT REV PROTEOMIC*, 4(1): 39-50.
8. Dihazi H, Müller C, Asif AR, Flad T, Elmaouhoub A, Müller GA (2007) Whole cell profiling and identification of galectin-1 as a potential marker of renal cell carcinoma Whole cell profiling and identification of galectin-1 as a potential marker of renal cell carcinoma Whole cell profiling and identification of galectin-1 as a potential marker of renal cell carcinoma. *Proteomics Clinical Applications*, 1(2): 200-14.
9. Dihazi H, Müller GA, Lindner S, Meyer M, Asif AR, Oellerich M, Strutz F (2007) Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. *CLIN CHEM*, 53(9): 1636-45.
10. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, MMKD SG, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. *J AM SOC NEPHROL*, 18(9): 2600-8.
11. Hagenah G, Herzum M, Grimm W (2007) Dynamic left main coronary artery stenosis caused by an aortic aneurysm after aortic valve replacement. *Heart (Internet-Ausgabe)*, 93(4): 518.
12. Hagenah GC, Wündisch T, Eckstein E, Zimmermann S, Holst F, Grimm W, Neubauer A, Lohoff M (2007) [Sepsis-like disease in an immunocompromised patient with a travel history to Mallorca]. *INTERNIST*, 48(7): 727-30.
13. Hartmann U, Muehle R, Reuss-Borst M (2007) Effects of a step-by-step inpatient rehabilitation programme on quality of life in breast cancer patients. A prospective randomised study. *ONKOLOGIE*, 30(4): 177-82.
14. Joshua F, Lassere M, Bruyn GA, Szkudlarek M, Naredo E, Schmidt WA, Balint P, Filippucci E, Backhaus M, Iagnocco A, Scheel AK, Kane D, Grassi W, Conaghan PG, Wakefield RJ, D'Agostino MA (2007) Summary findings of a systematic review of the ultrasound assessment of synovitis. *J RHEUMATOL*, 34(4): 839-47.
15. Kochsiek T, Koziol M, Müller GA (2007) Kalk im Körper. *Der Dialysepatient*, 1: 33-38.
16. Koepke ML, Weber M, Schulze-Lohoff E, Beirowski B, Segerer S, Gross O (2007) Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. *NEPHROL DIAL TRANSPL*, 22(4): 1062-9.
17. Koziol M, Scheel A, Bramlage C, Groene HJ, Müller GA, Strutz F (2007) Effective treatment of hepatitis C-associated immune-complex nephritis with cryoprecipitate apheresis and antiviral therapy. *CLIN NEPHROL*, 67(4): 245-9.
18. Koziol M, Schmid H, Cohen CD, Blaschke S, Hemmerlein B, Zapf A, Müller GA, Strutz F (2007) Potential role of fractalkine receptor expression in human renal fibrogenesis. *KIDNEY INT*, 72(5): 599-607.
19. Linker RA, Chan A, Sommer M, Koziol M, Müller GA, Paulus W, Gold R (2007) Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis. *J NEUROL*, 254(9): 1288-9.
20. Maass E, Müller GA, Heller T, Koziol M (2007) Decrease in serum tacrolimus level and rise in serum creatinine under late addition of cinacalcet in a renal transplant recipient with hyperparathyroidism: a case report. *TRANSPL P*, 39(10): 3468-70.
21. Markovic-Lipkovich J, Müller CA, Klein G, Flad T, Klatt T, Blaschke S, Wessels JT, Müller GA (2007) Neural cell adhesion molecule expression on renal interstitial cells. *NEPHROL DIAL TRANSPL*, -: -.
22. Meller J, Sahlmann CO, Scheel AK (2007) 18F-FDG PET and PET/CT in fever of unknown origin. *J NUCL MED*, 48(1): 35-45.
23. Müller GA, Müller CA, Dihazi H (2007) Clinical proteomics--on the long way from bench to bedside? *NEPHROL DIAL TRANSPL*, 22(5): 1297-300.

Abteilung "Nephrologie und Rheumatologie"

24. Pollack V, Sarközi R, Banki Z, Feifel E, Wehn S, Gstraunthaler G, Stoiber H, Mayer G, Montesano R, Strutz F, Schramek H (2007) Oncostatin M-induced effects on EMT in human proximal tubular cells: differential role of ERK signaling. *AM J PHYSIOL-RENAL*, 293(5): F1714-26.
25. Schindler C, Bramlage P, Thoenes M, Bramlage C, Kirch W (2007) Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugs. *CLIN DRUG INVEST*, 27(10): 707-17.
26. Schirmer C, Scheel AK, Althoff CE, Schink T, Eshed I, Lembcke A, Burmester GR, Backhaus M, Hamm B, Hermann KG (2007) Diagnostic quality and scoring of synovitis, tenosynovitis and erosions in low-field MRI of patients with rheumatoid arthritis: a comparison with conventional MRI. *ANN RHEUM DIS*, 66(4): 522-9.
27. Seitz G, Warmann SW, Armeanu S, Heitmann H, Ruck P, Hoffman RM, Fuchs J, Wessels JT (2007) In vitro photodynamic therapy of childhood rhabdomyosarcoma. *INT J ONCOL*, 30(3): 615-20.
28. Thedieck C, Kalbacher H, Kuczyk M, Müller GA, Müller CA, Klein G (2007) Cadherin-9 is a novel cell surface marker for the heterogeneous pool of renal fibroblasts. *PLoS ONE (Online-Journal)*, 2(7): e657.
29. Wakefield RJ, D'Agostino MA, Iagnocco A, Filippucci E, Backhaus M, Scheel AK, Joshua F, Naredo E, Schmidt WA, Grassi W, Moller I, Pineda C, Klauser A, Szkudlarek M, Terslev L, Balint P, Bruyn GA, Swen WA, Jousse-Joulin S, Kane D, Koski JM, O'Connor P, Milutinovic S, Conaghan PG, OMERACT UG (2007) The OMERACT Ultrasound Group: status of current activities and research directions. *J RHEUMATOL*, 34(4): 848-51.
30. Wessels JT, Busse AC, Mahrt J, Dullin C, Grabbe E, Mueller GA (2007) In vivo imaging in experimental preclinical tumor research--a review. *CYTOM PART A*, 71(8): 542-9.
31. Ziemer M, Wiesend CL, Vetter R, Weiss J, Blaschke S, Norgauer J, Mockenhaupt M (2007) Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis. *ARCH DERMATOL*, 143(6): 711-6.

Habilitationen

1. Benöhr P, Pathogenese und Prophylaxe der Cisplatin-induzierten Nephrotoxizität. Habilitation Universität Göttingen 2007.

Medizinische Dissertationen

1. Böhne P, Dr. med., Elimination des Röntgenkontrastmittels Iopromid bei niereninsuffizienten Patienten - Eine klinische Pilotstudie. Dissertation Universität Göttingen 2007.
2. Cassens S, Dr. med., Volumenregulation der epithelialen Zellen der dicken aufsteigenden Henle-Schleife der Kaninchenniere. Dissertation Universität Göttingen 2007.
3. Hartmann U, Dr. med., Besserung der Lebensqualität sowie der Angst und Depression bei Brustkrebspatientinnen durch Flexibilisierung von Dauer und Intervall einer stationären onkologischen Rehabilitationsmaßnahme. Dissertation Universität Göttingen 2007.
4. Hesse A, Dr. med., Bedeutung des ET-1/T-1370G-Polymorphismus für den Schweregrad der arteriellen Hypertonie sowie das Auftreten hypertensiver Endorganschäden. Dissertation Universität Göttingen 2007.
5. Popov A, Dr. med., Bedeutung des ET-1/C-198G-T-Polymorphismus für die Ausprägung und das Auftreten der essentiellen Hypertonie. Dissertation Universität Göttingen 2007.